Surrozen Initiates Dosing in Phase I Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
Surrozen, Inc. announced that the first subject has been dosed in its three-part Phase I clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.
[British Journal of Pharmacology] In vivo, investigators studied the role of Caspase-11 in several angiogenesis mouse models using Caspase-11 wild-type and knockout mice. In vitro, scientists detected the effects of Caspase-4 on endothelial functions and Notch signaling by depleting or overexpressing Caspase-4 in HUVECs.
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified the reversible SUMOylation of FGF receptor 1 (FGFR1) as an intrinsic fine-tuned mechanism in coordinating endothelial angiogenic signaling during neovascularization.